EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma

Xu-Yan Wang, Yuan Liao, Rui-Qi Wang, Yi-Tong Lu, Ying-Zhe Wang, Yu-Qi Xin, Dong-Ming Kuang iD, Xiang-Ming Lao, Junying Xu, Zhi-Ling Zhou, Kunhua Hu

Advanced Science · 2025

DOI: 10.1002/advs.202413682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Xu-Yan Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China. Hauptthemen laut MEDLINE: Sorafenib, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key-Area Research and Development Program of Guangdong Province, National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid development of resistance to sorafenib and subsequent hyperprogression in patients with advanced hepatocellular carcinoma (HCC) pose significant challenges, with the underlying mechanisms still largely unknown. Herein, sorafenib‐induced TRIB3 is identified as a liver‐specific determinant driving secondary resistance to sorafenib by facilitating the accumulation of protumorigenic neutrophils within tumors. Mechanistically, TRIB3, triggered by the sorafenib‐elicited ROS‐ER stress axis, operates in an NF‐κB‐dependent manner to upregulate CXCR1/2 ligands, subsequently promoting neutrophil recruitment into tumors. These enriched neutrophils enhance epithelial‐mesenchymal transition processes in malignant cells through the oncostatin M‐STAT3 pathway, thereby repurposing the therapeutic efficacy of sorafenib away from anti‐angiogenesis and toward lung metastasis. Clinically, elevated TRIB3 expression indicates inferior survival and unfavorable clinical efficacy of sorafenib in HCC patients. Correspondingly, strategies that either inhibiting TRIB3 upregulation or blocking its downstream signaling successfully augment the therapeutic efficacy of sorafenib and prevent sorafenib‐induced hyperprogression in vivo. The study thus identifies a pivotal mechanism of sorafenib resistance in HCC, centered on the TRIB3‐mediated recruitment of protumorigenic neutrophils and subsequent disease hyperprogression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibCarcinoma, HepatocellularLiver NeoplasmsLung NeoplasmsNeutrophilsProtein Serine-Threonine KinasesCell Cycle ProteinsHumansAnimalsMiceAntineoplastic AgentsCell Line, TumorDrug Resistance, NeoplasmMaleSignal TransductionEpithelial-Mesenchymal TransitionRepressor Proteins

Stichwörter der Autor:innen

TRIB3hepatocellular carcinomalung metastasisneutrophilsorafenib resistance

Substanzen

SorafenibProtein Serine-Threonine KinasesCell Cycle ProteinsTRIB3 protein, humanAntineoplastic AgentsRepressor Proteins

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
  • Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment (No. 2021B1212040004), Zhuhai Institute of Translational Medicine, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institu…
  • Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510630, China.
  • Department of Pharmacy, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China.
  • School of Life Sciences, Sun Yat-sen University, Guangzhou, 510275, China.

ORCID-Profile: Dong-Ming Kuang

Förderung

  • Key-Area Research and Development Program of Guangdong Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • Guangdong Provincial Basic and Applied Basic Research Fund Project Provincial Enterprise Joint Fund General Project
  • Research Start Project of Zhuhai People's Hospital
  • Fundamental Research Funds for the Central Universities
  • Guangzhou Municipal Institute Enterprise Joint Funding Project

Zitieren

APA

Wang, X. Y., Liao, Y., Wang, R. Q., Lu, Y. T., Wang, Y. Z., Xin, Y. Q., Kuang, D. M., Lao, X. M., Xu, J., Zhou, Z. L., & Hu, K. (2025). Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202413682

Vancouver

Wang XY, Liao Y, Wang RQ, Lu YT, Wang YZ, Xin YQ, et al. Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma. Advanced Science. 2025. doi:10.1002/advs.202413682

BibTeX
@article{Wang2025,
  author = {Wang, Xu-Yan and Liao, Yuan and Wang, Rui-Qi and Lu, Yi-Tong and Wang, Ying-Zhe and Xin, Yu-Qi and Kuang, Dong-Ming and Lao, Xiang-Ming and Xu, Junying and Zhou, Zhi-Ling and Hu, Kunhua},
  title = {Tribbles Pseudokinase 3 Converts Sorafenib Therapy to Neutrophil‐Mediated Lung Metastasis in Hepatocellular Carcinoma},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202413682}
}
Kostenlos starten →